Theratechnologies Inc. THTX
At closeSep 25, 2025, 4:00 PM EDT
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 80.92M
- Revenue (ttm)
- 84.32M
- Profit margin
- -3.74%
- EPS (ttm)
- -0.04
- Shares out
- 45.98M
- Forward P/E
- 16.00
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 3.27M
- Avg volume
- 67.21K
- Open
- 3.36
- Previous close
- 3.39
- Day's range
- 3.36 – 3.39
- 52-week range
- 1.08 – 2.58
- Beta
- 1.73
- Analysts
- Buy
- Price target
- 3.79 (+11.7%)
2Y +1.48 (+77.49%)
Key statistics
- Enterprise value
- 101.28M
- PEG ratio
- 0.00
- Price / sales
- 0.96
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 8.40%
- Free cash flow
- -6.60M
- Total cash
- 38.86M
- Total debt
- 57.83M
- Return on equity
- 0.00%
- Short % of float
- 0.10%
- 50-day average
- 1.33
- 200-day average
- 1.33
Analyst view
Consensus: buy
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.069.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 10, 2024 | Aug 1, 2024 | 0.00 | 0.06 | — | — |
| Jul 10, 2024 | May 1, 2024 | 0.00 | 0.02 | — | — |
| Apr 10, 2024 | Feb 1, 2024 | 0.00 | -0.10 | — | — |
| Feb 21, 2024 | Nov 1, 2023 | 0.00 | -0.08 | — | — |
| Sep 26, 2023 | Aug 1, 2023 | 0.00 | -0.03 | — | — |
| Jul 12, 2023 | May 1, 2023 | 0.00 | -0.40 | — | — |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- theratech.com
News
Theratechnologies Announces Completion of Acquisition by Future Pak 
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak 
Theratechnologies Inc. (TH:CA) Special Meeting Of Shareholders Of Theratechnologies Call (Transcript) 
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak 
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy 
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak 
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak 
'South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts' - Bloomberg News 
Theratechnologies Reports Financial Results for the Second Quarter 2025 
Earnings Scheduled For July 9, 2025
Your note
Sign in to keep a note on THTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Arena (Joseph) | Director of Issuer | Acquisition or disposition in the public market | Oct 20, 2022 | 15,000 |
| Holler (Frank A) | Director of Issuer | Acquisition or disposition in the public market | May 2, 2022 | 39,000 |
| Lafond (Jocelyn) | Senior Officer of Issuer | Acquisition or disposition in the public market | Jul 20, 2022 | 18,000 |
| Svoronos (Dawn A) | Director of Issuer | Exercise of options | Oct 19, 2022 | 323,600 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Soleus Capital Management, L.P. | 10.44% | 4,801,376 | 8.45M | Sep 29, 2024 |
| AIGH Capital Management LLC | 8.10% | 3,725,204 | 6.56M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 5.83% | 2,682,228 | 4.72M | Sep 29, 2024 |
| Morgan Stanley | 4.90% | 2,253,894 | 3.97M | Sep 29, 2024 |
| National Bank of Canada/FI | 0.41% | 186,815 | 328.79K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.32% | 145,254 | 255.65K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 25,681 | 45.20K | Oct 30, 2024 |